BG Medicine, Inc. to Present at 24th Annual Piper Jaffray Healthcare
WALTHAM, Mass., Nov. 20, 2012 (GLOBE NEWSWIRE) -- BG Medicine, Inc.
(Nasdaq:BGMD), a company focused on the development and commercialization of
novel cardiovascular diagnostics, announced today that Eric Bouvier, BG
Medicine's President and CEO, will presenting at the 24th Annual Piper Jaffray
Healthcare Conference on November 27 at 3:00 PM Eastern Time (ET) in New York
The fireside chat style presentation will be webcast live and archived for 30
days on BG Medicine's Investor Relations website at ir.BG-medicine.com.
About BG Medicine, Inc.
BG Medicine, Inc. (Nasdaq:BGMD) is a diagnostics company focused on the
development and commercialization of novel cardiovascular diagnostics to
address significant unmet medical needs, improve patient outcomes and reduce
healthcare costs. The Company's first commercialized product, the BGM
Galectin-3^® test for use in patients with chronic heart failure, is available
in the United States and Europe. BG Medicine is also developing the
CardioSCORE^TM test, a blood test designed to aid in the assessment of an
individual's risk for near-term major cardiovascular events.For additional
information about BG Medicine, heart failure and galectin-3 testing, please
visit www.bg-medicine.comand www.galectin-3.com.
The BG Medicine Inc. logo is available at
CONTACT: Chuck Abdalian
EVP & Chief Financial Officer
BG Medicine Inc. logo
Press spacebar to pause and continue. Press esc to stop.